Insulin in Medical Technology

Oramed Pharmaceuticals Announces Launch of Phase 2B Clinical Trials in South Africa of its Oral Insulin Capsule

JERUSALEM, May 5 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTC: ORMP) ( http://www.oramed.com ), a developer of oral delivery systems, announced that Phase 2b clinical trials will commence this week on 30 Type 2 Diabetic volunteers. The study is intended to evaluate the safety, t...

Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA)

JERUSALEM, March 25 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ), a developer of oral delivery systems, announced today that it has been selected to present the results from the study, entitled, "Open Label Study to Assess the Safety, Pharma...

Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository

JERUSALEM, Israel, February 4 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB), a developer of alternative drug delivery systems, announced today that it has concluded a proof of concept study in South Africa of insulin suppositories, ORMD-0802, using its proprietary tec...

FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes

BRIDGEWATER, N.J., Oct. 29 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) approved Apidra(R) (insulin glulisine [rDNA origin] injection) to improve glycemic control in children (4 years and older) with diabetes mellitus. The approval...

Oramed Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository

JERUSALEM, October 23 /PRNewswire-FirstCall/ -- - An Insulin Suppository Represents an Important Development in the Treatment of Diabetes as it Provides a Painless Alternative for Effective Insulin Delivery Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB; http://www.oramed.com ), a developer...

Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics

Study to Assess the Safety and Efficacy of ORMD 0801, Oral Insulin Capsule, on Type 1 Diabetics JERUSALEM, Israel, September 24 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ), a developer of oral delivery systems, announ...

MannKind Reports Positive Data from a Phase 3 Clinical Study of Technosphere Insulin in Type 1 Diabetes

Study 009 meets its primary endpoint of non-inferiority to a rapid-acting insulin analog VALENCIA, Calif., Sept. 16 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD ) today released preliminary top-line results from a Phase 3 clinical study of the Techno...

Modified Insulin Most Effective For Controlling Post-Meal Blood Sugar Levels

ROCKVILLE, Md., Sept. 15 /PRNewswire-USNewswire/ -- Pre-mixed insulin analogues, a modified form of conventional pre-mixed human insulin, are more effective than long-acting analogues for controlling high blood sugar levels after meals in patients with type 2 diabetes, according to a report fu...

Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)

JERUSALEM, Israel, August 18 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ), a developer of oral delivery systems, announced today that its abstract, entitled "Open Label Study to Assess the Safety, Pharmacokinetics (PK) and Pharmacodynamics (...

Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling

Intercept Pharmaceuticals is Advancing Bile Acid-Derived Small Molecules with Potential Applications in Treating Metabolic Diseases NEW YORK, Aug. 7 /PRNewswire/ -- Historically, bile acids have been recognized primarily as natural detergents that regulate the absorption of dietary lipid...

New Survey Explores the Impact of Insulin Injections and Communications Between Patients and Healthcare Providers

CHICAGO, Aug. 7 /PRNewswire/ -- The American Association of Diabetes Educators (AADE) today announced results from a survey conducted by Harris Interactive highlighting communication between people with diabetes that require insulin injections and their healthcare providers. According to the s...

Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule

The Trial Demonstrated the Safety and Efficacy of the ORMD 0801- Oral Insulin Capsule JERUSALEM, Israel, August 6 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP)( http://www.oramed.com ), a developer of oral delivery systems, announced today suc...

Treatment Corrects Severe Insulin Imbalance in Animal Studies

--Could Become First Effective Drug for Rare Genetic Disorder in Children-- PHILADELPHIA, July 31 /PRNewswire-USNewswire/ -- Researchers have used a drug to achieve normal levels of blood sugar in animals genetically engineered to have abnormally high insulin levels. If this approach succe...

Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials

JERUSALEM, July 31 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP) ( http://www.oramed.com ), a developer of oral delivery systems, announced today that it will hold a conference call on August 6, 2008 at 10:30 AM EDT to present the results of its Phase 2A clinical trials ...

Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes

Two Regimens Including Lantus(R) and Apidra(R) Resulted in Significant Reductions in A1C in Patients with Type 2 Diabetes, Whatever the Algorithm Used BRIDGEWATER, N.J., July 22 /PRNewswire/ -- Results from the "Adjust to Target in Type 2 Diabetes: Comparison...

Emisphere Announces Data From Independent Clinical Study of Effects of Oral GLP-1 on Glucose and Insulin Concentrations

GLP-1 Has Potential to Treat Type 2 Diabetes Using Emisphere's Eligen(R) Technology CEDAR KNOLLS, N.J., July 8 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS ) today announced findings from a clinical study assessing the oral delivery of GLP...

Novel Testosterone Gel Significantly Improves Insulin Sensitivity and Sexual Function in Hypogonadal Men With Type 2 Diabetes and Metabolic Syndrome

New Data Highlights the Need for Testosterone Screening in At-Risk Hypogonadal Men BEDMINSTER, N.J., June 17 /PRNewswire/ -- New data from a 12-month, international, multi-center study showed that treatment for low testosterone with Tostran(R), a topical, metered ...

Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin

Results from a 24-week multi-center, randomized, open-label study presented at ADA 2008 SAN FRANCISCO, June 9 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) today announced data showing that the use of mealtime SYMLIN(R) (pramlintide acetate)...

Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability

SAN FRANCISCO, June 9 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced new Phase I data for the company's diabetes mellitus program at the American Dia...

New Study Confirms Dose-Accuracy of SoloSTAR(R) Prefilled Insulin Pen

100% of Insulin Doses Administered Were Delivered Within Pre-Determined Guidelines and Standard Dosing Limitations BRIDGEWATER, N.J., May 5 /PRNewswire-FirstCall/ -- A new study examining the dose accuracy of the SoloSTAR(R) disposable insulin pen, prefilled with Lantus(R) (insul...

Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients

SAN CARLOS, Calif., April 9, 2008 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) announced today that it has ceased all negotiations with potential partners for its inhaled insulin programs as a result of new data analysis from ongoing clinical trials conducted by Pfizer Inc. A...

Elite Team of Cyclists with Type 1 Diabetes Powers Forward in 2008 Sponsored by Rapid-Acting Insulin Apidra(R)

- Inspirational Team of Athletes - Team Type 1 - Spreads Messages of Hope to Others with Diabetes and Steers Toward Its Ultimate Goal of Tour de France Competition BRIDGEWATER, N.J., April 2, 2008 /PRNewswire-FirstCall/ -- Sanofi-a...

New Data Shows Ranexa(R) Increases Glucose-Stimulated Insulin Secretion

CHICAGO, March 31 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX ) announced today that preclinical research presented at the American College of Cardiology 57th Annual Scientific Session in Chicago showed that ranolazine increased glucose-stimulated insulin secretion (GSIS) in...

Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin

ORLANDO, Fla., Nov. 7 /PRNewswire-FirstCall/ -- A retrospective analysis of healthcare claims in more than 20,000 patients with type 2 diabetes from an integrated U.S. national managed care database found that the initiation of insulin therapy with insulin glargine was associated with a lower ...

Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for Insulin Nasal Spray to Treat Diabetes

- Rapid-Acting, Non-Invasive Nasal Spray Dosage form is Patient Friendly and Avoids Potential Safety Concerns of Pulmonary Delivery - BOTHELL, Wash., Sept. 26 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK ) announced today the start of a Phase 2 clinical tri...

MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study

MONMOUTH JUNCTION, N.J., Aug. 6 /PRNewswire/ -- MicroDose Technologies, Inc., a privately held drug delivery and specialty pharmaceuticals company, today announces top line results from a glucose clamp study of the QDose inhaled insulin product. MicroDose, through its joint venture with Vectur...

Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results

Company's TPM-02/Insulin Significantly Lowered Blood Glucose without Producing Any Adverse Reactions Phase 2 Trial Expected to Begin upon Ethics Approval with Results due in Q1 2008 MELBOURNE, Australia, Aug. 8 /PRNewswire-FirstCall/ -- Pho...

Sanofi Aventis: People With Type 2 Diabetes Treated With LANTUS(R) and APIDRA(R) Achieved Greater Reductions in A1C Than Those Treated With Pre-mixed Insulin

PARIS, September 10 /PRNewswire-FirstCall/ -- - Abstracts 186 and 1003 Sanofi-aventis announced today that results from two studies, GINGER and LACE, presented at the 44th annual meeting of the European Association for the Study of Diabetes (EASD) demonstrated that a basal-bolus insulin re...

Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin

DALLAS, Dec. 7 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP) announced today that it has demonstrated the ability, using the company's proprietary Cobalamin(TM) technology, to significantly reduce glucose levels in an animal model of diabetes, through its or...

GTx Announces Ostarine Improved Insulin Resistance among Elderly Patients in a Recently Completed Phase II Clinical Trial

MEMPHIS, Tenn.--(BUSINESS WIRE)--Apr 17, 2007 - GTx, Inc. (NASDAQ: GTXI) announced today that data from a recently conducted Phase II Ostarine(TM) clinical trial of 60 elderly men and 60 postmenopausal women revealed that insulin and glucose levels were reduced and insulin resistance was improved a...

Baxter Presents Phase I Inhaled Insulin Study Results at Respiratory Drug Delivery Conference

Findings Suggest Insulin Powder Produced Using Baxter's PROMAXX Microsphere Technology was Absorbed Systemically with No Reported Cough or Shortness of Breath PARIS, April 20, 2007 /PRNewswire-FirstCall/ -- Baxter Healthcare Corporation announced results of a Phase I study that evaluated pulmonary...

Phosphagenics to Commence Phase 1b Transdermal Insulin Clinical Trial in Second Quarter

MELBOURNE, Australia, May 03, 2007 /PRNewswire-FirstCall/ -- Phosphagenics Limited (AIM: PSG) announced today that the Company intends to initiate a Phase 1b clinical trial to demonstrate the efficacy and safety of the improved formulation of its transdermal insulin product, TPM-02/Insulin, contai...

Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23

SAN DIEGO, June 21, 2007 /PRNewswire-FirstCall/ -- Orexigen(TM) Therapeutics, Inc. , a biopharmaceutical company focused on the treatment of central nervous system disorders with an initial focus on obesity, today announced that the Company will present data about its lead obesity product candidat...

SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference

- Canadian Biotechnology Company updates progress and upcoming milestones on its insulin program - CALGARY, June 26, 2007 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. , a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular disease, today announ...

Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership

...ch strikes children and adults suddenly and requires multiple injections of insulin daily or a continuous infusion of insulin through a pump. Insulin, however, is not a cure for diabetes, nor does it p...

Debiopharm Group and Mercury Therapeutics, Inc. Sign an Exclusive License Agreement for the Development and Commercialisation of Debio 0930

...n this transaction by Katan Associates. About Diabetes Diabetes is a disease in which the body does not produce or properly use insulin. insulin is a hormone that is needed to convert sugar, starches and other food into energy needed for daily life. The cause of diabetes continues to be a myste...

TWO NEW KLRI PEER-REVIEWED PUBLICATIONS: Hormone Therapy May Reduce Atherosclerosis in Women Close to Menopause; Growth Hormone May Increase Risk of Diabetes, Improve Lipid Profile in Men

...riod of six months. The study found that GH caused insulin resistance (the body's inability to respond to and use the insulin it produces) to increase, yet it had a beneficial ...ids on glucose tolerance, elevated cholesterol and insulin sensitivity--changes in older adults that occur as...

Diabetes Gene Raises Odds of Lower Birth Weight

...ccurs either when the pancreas produces too little insulin or when the body cannot efficiently use the insulin that is produced. Formerly called adult-onset dia...ght -- a finding that supports the so-called fetal insulin hypothesis. Previous studies by European diabetes ...

Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)

...oming pregnant. Talk to your doctor if you are pregnant, planning to become pregnant, breastfeeding, or planning to breastfeed. When taking ACTOS with insulin or sulfonylureas, you may be at risk for low blood sugar. Some people taking ACTOS may experience flulike symptoms, mild-to-moderate swelling of legs ...

Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study

...lone or in combination with a sulfonylurea. Subjects were randomized to receive exenatide once weekly 2 milligrams by subcutaneous injection weekly or insulin glargine injections administered daily in a variable dose determined by patient blood sugar levels. There was no lead-in or wash-out period. The prima...